ArticleJournal of the American Academy of Dermatology2014
Palmoplantar psoriasis is associated with greater impairment of health-related quality of life compared with moderate to severe plaque psoriasis.
Article in Journal of the American Academy of Dermatology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 42 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
42 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Small-Molecule Inhibitors and Biologics for Palmoplantar Psoriasis and Palmoplantar Pustulosis: A Systematic Review and Network Meta-Analysis.American journal of clinical dermatology · 2024Pooled it
- Long-Term Safety and Efficacy of Risankizumab to Treat Moderate-to-Severe Plaque Psoriasis: Final LIMMitless Phase 3, Open-Label Extension Trial Results.American journal of clinical dermatology · 2025Trial
- Risankizumab in Japanese patients with moderate-to-severe palmoplantar pustulosis: Results from the randomized, phase 3 JumPPP study.The Journal of dermatology · 2025Trial
- Comparison of the Efficacy and Safety of Apremilast and Methotrexate in Patients with Palmoplantar Psoriasis: A Randomized Controlled Trial.American journal of clinical dermatology · 2021Trial
- Patient-reported foot dysfunction and quality of life in psoriasis: the independent association of psoriatic arthritis beyond skin disease severity.Clinical rheumatology · 2026Article
- Article
- Differentiation of Palmoplantar Psoriasis, Palmoplantar Pustulosis and Hyperkeratotic Palmoplantar Eczema Using Proteomic Analysis of Tape Strip Samples.Experimental dermatology · 2026Observational
- Efficacy of a topical polyphenol-based formulation in palmoplantar psoriasis: an observational study.Dermatology reports · 2026Article
- Tildrakizumab in Managing Psoriasis with Involvement of Difficult-to-Treat Areas: A Multicenter Real-Life Retrospective Study.Journal of clinical medicine · 2026Article
- Th17 cells with regulatory phenotype are the main IL-17F and IL-26 producers in palmoplantar pustulosis.JCI insight · 2025Article
- Palmoplantar Psoriasis: Epidemiological and Clinical Features and Impact on Quality of Life.Dermatology practical & conceptual · 2024Article
- Difficult-to-treat psoriatic arthritis: refining the definition using a statistical model in a real-life cohort.Frontiers in medicine · 2024Article
- Brodalumab in the Treatment of Plaque Psoriasis Localized in Difficult-to-Treat Areas: A Narrative Review.Dermatology practical & conceptual · 2023Review
- Identifying risk factors for cutaneous disease among solid organ transplant recipients: A retrospective review.JAAD international · 2023Article
- Article
- Palmoplantar Pustulosis has a Greater Disease Burden than Plaque Psoriasis: Real-World Evidence From the CorEvitas Psoriasis Registry.Journal of psoriasis and psoriatic arthritis · 2023Article
- Challenges in Psoriatic Disease Addressed by Fixed-Combination Halobetasol Propionate 0.01% and Tazarotene 0.045% Lotion.The Journal of clinical and aesthetic dermatology · 2023Review
- Comparative effectiveness of biologics for patients with moderate-to-severe psoriasis and special area involvement: week 12 results from the observational Psoriasis Study of Health Outcomes (PSoHO).Frontiers in medicine · 2023Article
- Influences of methotrexate iontophoresis on functional lifestyle disabilities, functional capacity, and pain in patients with plantar psoriasis.Turkish journal of physical medicine and rehabilitation · 2022Article
- Narrative Review of the Emerging Therapeutic Role of Brodalumab in Difficult-to-Treat Psoriasis.Dermatology and therapy · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
backgroundThe impact of palmoplantar psoriasis on health-related quality of life (QoL) is largely unknown.
objectiveWe sought to compare clinical characteristics and patient-reported outcomes between patients with palmoplantar psoriasis and moderate to severe plaque psoriasis.
methodsWe conducted a cross-sectional study of patients with plaque psoriasis (N=1153) and palmoplantar psoriasis (N=66) currently receiving systemic or light treatment for psoriasis.
resultsPatients with palmoplantar psoriasis were more likely to report Dermatology Life Quality Index scores that correspond to at least a moderate impact on QoL (odds ratio [OR] 2.08; 95% confidence interval [CI] 1.20-3.61); problems with mobility (OR 1.98; 95% CI 1.10-3.58), self-care (OR 3.12; 95% CI 1.24-7.86), and usual activities (OR 2.47; 95% CI 1.44-4.22) on the European Quality of Life-5 Dimensions questionnaire; and heavy topical prescription use of at least twice daily in the preceding week (OR 2.81; 95% CI 1.63-4.85) than those with plaque psoriasis. LIMITATIONS: Our assessment tools may not account for all dimensions of health-related QoL affected by palmoplantar disease, and these results may not be generalizable to patients with milder forms of psoriasis.
conclusionPatients with palmoplantar psoriasis experience greater health-related QoL impairment and are more likely to report heavy use of topical prescriptions than those with moderate to severe plaque psoriasis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.